SciSparc (SPRC) Return on Capital Employed (2017 - 2022)

SciSparc (SPRC) posted Return on Capital Employed of 67.36% for Q4 2022, up 108.27% sequentially from 814.52% in Q2 2019.

SciSparc (SPRC) Return on Capital Employed (2017 - 2022) Analysis & Trends

SciSparc has reported Return on Capital Employed for 4 years, with the latest figure at 67.36% in Q4 2022.

Quarterly Return on Capital Employed changed N/A year-over-year to 67.36% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 67.36% (changed N/A YoY) and the FY2025 annual result came in at 124.4%, down 4628.0% from the prior year.
Return on Capital Employed rose to 67.36% in Q4 2022 per SPRC's latest filing, from 814.52% in the prior quarter.
Over five years, Return on Capital Employed peaked at 67.36% in Q4 2022 and troughed at 814.52% in Q2 2019.
A 3-year average of 271.54% and a median of 67.47% in 2018 frame the typical range for Return on Capital Employed.
The sharpest annual moves came in 2018 and 2019: Return on Capital Employed plunged 5904 bps in 2018, then sank 74705 bps in 2019.
Over 3 years, Return on Capital Employed stood at 67.47% in 2018, then sank by 1107 bps to 814.52% in 2019, then surged by 108 bps to 67.36% in 2022.
According to Business Quant data, Return on Capital Employed over the past three periods registered 67.36%, 814.52%, and 67.47% for Q4 2022, Q2 2019, and Q2 2018 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	20.76%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	10.74%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-38.20%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.68%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	26.09%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-50.93%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	7.88%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-6.85%
10	SciSparc	836,385.99	836,385.99	-	-

Download Data